PeptidePedia The community reference

Contributions of ScopeSeverin

User contributions·48 logged edits·page 1 of 1

Contributions by ScopeSeverin, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 855 edits includes activity predating the current log.

  1. 10:35, 29 Jun 2026 (diff | hist) Talk:Sharps disposal 1,096 +215 /* Colour-coding table is England-specific and presented as general */ reply
  2. 15:10, 14 Jun 2026 (diff | hist) Talk:PeptideMeter 885 +91 /* Small-sample rankings */ reply
  3. 09:35, 9 Jun 2026 (diff | hist) Talk:Peptide 1,096 +60 /* Scope creep */ reply
  4. 11:20, 8 Jun 2026 (diff | hist) Talk:Peptide 674 +189 /* Scope creep */ new section
  5. 13:50, 1 Jun 2026 (diff | hist) Talk:Prescribing information 748 +60 /* No label for research material */ reply
  6. 10:40, 22 May 2026 (diff | hist) Talk:Methionine oxidation 537 +149 /* Polysorbate peroxides */ new section
  7. 16:14, 18 May 2026 (diff | hist) SinoPep 18,360 ±0 m rm a duplicated category
  8. 09:15, 15 May 2026 (diff | hist) Talk:Limit of detection 537 +154 /* Threshold table scope */ new section
  9. 11:05, 24 Apr 2026 (diff | hist) Talk:Lyophilisation 1,507 +171 /* Section on unregulated ambient shipping — is it in scope here? */ reply
  10. 15:30, 21 Apr 2026 (diff | hist) Talk:Lyophilisation 1,085 +310 /* Section on unregulated ambient shipping — is it in scope here? */ new section
  11. 14:33, 19 Apr 2026 (diff | hist) Talk:Proglucagon 748 +171 /* Assay cross-reactivity deserves its own article */ reply
  12. 10:05, 18 Apr 2026 (diff | hist) Talk:Global access disparity 1,033 +175 /* Framing of the access argument */ reply
  13. 11:34, 17 Apr 2026 (diff | hist) Talk:Beyond-use date 1,581 +163 /* Community dating practice: describe or omit? */ reply
  14. 10:52, 14 Apr 2026 (diff | hist) Talk:Beyond-use date 948 +337 /* Community dating practice: describe or omit? */ new section
  15. 10:27, 5 Apr 2026 (diff | hist) Talk:Cold chain 2,003 +231 /* RfC: should this article cover consumer shipping practice? */ reply
  16. 13:15, 2 Apr 2026 (diff | hist) Talk:Regulatory status by jurisdiction 611 +169 /* Structure of the jurisdiction material */ reply
  17. 11:38, 2 Apr 2026 (diff | hist) Talk:Cold chain 1,159 +306 /* RfC: should this article cover consumer shipping practice? */ reply
  18. 13:15, 30 Mar 2026 (diff | hist) Talk:Grey market 611 +140 /* Is the term useful here at all? */ reply
  19. 10:22, 30 Mar 2026 (diff | hist) Talk:Semaglutide 537 +180 /* How much detail on research-chemical material? */ new section
  20. 09:20, 23 Mar 2026 (diff | hist) Talk:GLP-1 receptor agonist 1,096 +103 /* Scope: how much research-chemical material belongs here? */ reply
  21. 14:05, 22 Mar 2026 (diff | hist) Talk:GLP-1 receptor agonist 674 +173 /* Scope: how much research-chemical material belongs here? */ new section
  22. 09:15, 4 Mar 2026 (diff | hist) Talk:Sigma-Aldrich (Shanghai) Trading 537 +301 /* Trading company or synthesis house, and whether the article should say */ new section
  23. 13:20, 20 Feb 2026 (diff | hist) Talk:Contraindications of incretin therapy 611 +113 /* Contraindication is a labelling concept */ reply
  24. 09:12, 14 Feb 2026 (diff | hist) Talk:Temperature excursion 1,940 +217 /* Is a community-reported stability observation usable evidence at all? */ reply
  25. 10:30, 13 Feb 2026 (diff | hist) Talk:Dulaglutide 400 +128 /* Is this a peptide article at all? */ new section
  26. 11:26, 5 Oct 2025 (diff | hist) Talk:AmbioPharm 1,033 +339 /* Notability, and what a long registry record does not establish */ reply
  27. 09:15, 2 Oct 2025 (diff | hist) Talk:AmbioPharm 400 +489 /* Notability, and what a long registry record does not establish */ new section
  28. 11:26, 7 Sep 2025 (diff | hist) Talk:GenScript Peptides 1,244 +389 /* Notability, and what a long registry record does not establish */ reply
  29. 09:15, 4 Sep 2025 (diff | hist) Talk:GenScript Peptides 400 +489 /* Notability, and what a long registry record does not establish */ new section
  30. 10:05, 2 Sep 2025 (diff | hist) Talk:PolyPeptide Group (Hangzhou) 400 +584 /* Notability, and what a printed chromatogram does and does not establish */ new section
  31. 11:33, 16 Aug 2025 (diff | hist) Talk:Shenzhen Hybio Pharmaceutical 1,033 +196 /* Notability, and what a long registry record does not establish */ reply
  32. 09:20, 13 Aug 2025 (diff | hist) Talk:Shenzhen Hybio Pharmaceutical 400 +591 /* Notability, and what a long registry record does not establish */ new section
  33. 18:42, 5 Aug 2025 (diff | hist) Glossary of peptide terminology 4,744 ±0 m expand §Clinical and evidence
  34. 10:31, 17 Jun 2025 (diff | hist) Talk:SinoPep 1,244 +182 /* Notability, and whether a documentary distinction is a notable one */ reply
  35. 09:15, 10 Jun 2025 (diff | hist) Talk:SinoPep 400 +320 /* Notability, and whether a documentary distinction is a notable one */ new section
  36. 16:44, 26 Apr 2025 (diff | hist) Talk:Sigma-Aldrich (Shanghai) Trading 1,033 +136 /* A distributor that does not claim manufacture, and what the article may infer from that */ reply
  37. 09:33, 23 Apr 2025 (diff | hist) Talk:ChinaPeptides 822 +195 /* Which name should the article title use? */ reply
  38. 10:05, 19 Apr 2025 (diff | hist) Talk:Sigma-Aldrich (Shanghai) Trading 400 +613 /* A distributor that does not claim manufacture, and what the article may infer from that */ new section
  39. 01:13, 8 Mar 2025 (diff | hist) Glucagon-like peptide-1 10,239 +47 split §Physiology from §Pharmacological exploitation
  40. 09:14, 19 Feb 2025 (diff | hist) Talk:GL Biochem (Shanghai) 959 +260 /* Upstream versus retail: is this the same kind of article? */ reply
  41. 13:19, 2 Feb 2025 (diff | hist) Talk:Shanghai Wibson Biotechnology 611 +351 /* Notability: what a five-year registry history establishes */ reply
  42. 14:49, 29 Jan 2025 (diff | hist) Trial data comparison 2,220 +171 add the trial and year to each row of the comparison
  43. 10:26, 11 Jan 2025 (diff | hist) Talk:Sangon Biotech 1,033 +75 /* Scope: is this a peptide supplier article at all? */ reply
  44. 11:04, 8 Jan 2025 (diff | hist) Talk:Sangon Biotech 400 +295 /* Scope: is this a peptide supplier article at all? */ new section
  45. 12:15, 21 Nov 2024 (diff | hist) Talk:Shanghai Sigma-Audley New Material Technology 611 +269 /* Notability and the registered business scope */ reply
  46. 21:35, 23 Oct 2024 (diff | hist) Insulin syringe unit conversion 1,462 +160 rm the administration advice; the tool computes, it does not instruct
  47. 10:28, 10 Oct 2024 (diff | hist) Talk:Nantong Guangyuan Chemical 1,033 +129 /* Multiple trading names: which is the title? */ reply
  48. 11:31, 15 Aug 2024 (diff | hist) Talk:WuXi TIDES 1,033 +215 /* Notability, and the name problem */ reply